Venture consortium continues to support Cara Therapeutics in its series D round after more than $55m in five year.
Cara Therapeutics, a US-based biotech company focused on pain relief and backed by Japanese conglomerate Mitsubishi, has raised $15m in its series D round.
Venture capital firm Rho Ventures led the round as a new investor, and was joined by repeat VC investors Alta Biopharma, Ascent Biomedical Ventures, Devon Park BioVentures, MVM Life Science Partners, Connecticut state’s CT Innovations, and Mitsubishi International’s MC Life Science Ventures.
Cara closed its extended series C round at $36.3m two years ago…
